Workshop on the challenges in substitution of nonbiological complex drugs

American Journal of Health-System Pharmacy

Volumn 70, Issue 21, 2013, Pages 1879-1880

  Shah, Vinod P ^a   Vulto, Arnold G ^b   Mühlebach, Stefan ^c  

^a University Medical Center ^*  (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Vifor (International) Inc   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; DRUG; IRON SACCHARATE; NONBIOLOGICAL COMPLEX DRUG; UNCLASSIFIED DRUG;

DRUG INDICATION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; LETTER; THERAPEUTIC EQUIVALENCE; CHEMISTRY; DRUG APPROVAL; DRUG SUBSTITUTION; EDUCATION; HUMAN; LEGAL ASPECT; METABOLISM;

DRUG APPROVAL; DRUG SUBSTITUTION; EDUCATION; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84901738787     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130141     Document Type: Letter

References (8)

1. Schellekens H, Klinger E, Mühlebach S et al. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol. 2011; 59:176-83.
2. Borchard G, Flühmann B, Mühlebach S. Nanoparticle iron medicinal products - requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Regul Toxicol Pharmacol. 2012; 64:324-8.
3. Rottembourg J, Kadri A, Leonard E et al. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant. 2011; 26:3262-7.
4. Lee ES, Park BR, Kim JS et al. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr Med Res Opin. 2013; 29:141-7.
5. Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin. 2012; 28:241-3.
6. Toblli JE, Cao G, Oliveri L et al. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Drug Res. 2009; 59:176-90.
7. European Medicines Agency. Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/04/WC500105048.pdf (accessed 2012 Aug 17).
8. Food and Drug Administration. Draft guidance on iron sucrose (Mar 2012). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM297630.pdf (accessed 2013 May 20).